Anti-PD-1/PD-L1 monoclonal antibodies bind to PD-1 and PD-L1 receptors on T cells and tumor cells, respectively, disrupt the PD-1/PD-L1 interaction, and reactivate anti-tumor T cell responses. This evidence concerns the gene PDCD1 and neoplasm.